Please assess the completion status of the following clinical trial:

Trial Title: Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of histologically documented MM previously enrolled on UARK 98-026 with relapsed or progressive disease after at least one autologous transplant.~* Patient has measurable disease in which to capture response, defined as:~* Serum M-protein level \> 1.0 gm/dl (10.0 g/L) measured by serum protein electrophoresis or immunoglobulin electrophoresis~* Urinary M-protein excretion \> 200 mg/24 hrs~* Bone marrow plasmacytosis of \> 30percent by bone marrow aspirate and/or biopsy~* Serum Free Light Chains (By the Freelite test) \> 10 mg/dL with an abnormal kappa/lambda ration.~* 50percent increase in size of lytic and/or focal lesions or development of new lesions recognized by radiographic studies.~* Performance status of 2 as per SWOG scale, unless PS of 3-4 based solely on bone pain.~* Patients must have a platelet count 50,000/mm3, unless the low platelet count is due to documented (\>30 percent) extensive myeloma infiltration of the bone marrow.~* Patients must have adequate renal function defined as serum creatinine \< 2.5 mg/dl.~* Patients must have adequate hepatic function defined as serum transaminases and direct bilirubin \< 2 x the upper limit of normal.~* Pregnant or nursing women may not participate. Women of childbearing potential must have a negative pregnancy documented within one week of registration. Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.~* Male or female adults of at least 18 years of age.~* Patients must have signed and IRB-approved written informed consent form and demonstrate willingness to meet follow-up schedule and study procedure obligations~* \> 5 x 106 CD34 cells/kg in storage strongly desired, but not mandated~Exclusion Criteria:~* Not previously enrolled on UARK 98-026.~* Has received salvage therapy after coming off UARK 98-026.~* Evidence of POEMS Syndrome..~* Significant neurotoxicity interfering with ADL.~* Platelet count \< 50,000/mm3~* Clinically significant hepatic dysfunction as noted by bilirubin or AST \>3 times the upper normal limit or clinically significant concurrent hepatitis.~* New York Hospital Association (NYHA) Class III or Class IV heart failure.~* Myocardial infarction within the last 6 months.~* Truly non-secretory MM (no increase in serum free-light chains) in the absence of bone marrow plasmacytosis and MRI-defined focal lesions with CT-FNA-proven MM~* Uncontrolled, active infection requiring IV antibiotics.~* Patients with a history of treatment for clinically significant ventricular cardiac arrhythmias.~* Poorly controlled hypertension, diabetes mellitus, or other serious or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol.~* Pregnant or potential for pregnancy. Women of childbearing potential will have a pregnancy test at screening, and will be required to use a medically approved contraceptive method. Pregnancy testing will be performed prior to administration of each dose of study drug.~* Breast-feeding women may not participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VTD = Velcade, Thal, and Dex (Type: EXPERIMENTAL): VTD = Velcade, Thalidomide, and Dexamethasone
- VMD = velcade, melphalan, and dex (Type: EXPERIMENTAL): VMD = velcade, melphalan, and dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).